Microba Life Sciences Limited (MAP.AX)
AUD 0.19
(0.0%)
AUD 0.19
(0.0%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 | 12.09 Million AUD | 123.06% |
| 2023 | 5.42 Million AUD | 15.6% |
| 2022 | 4.68 Million AUD | 25.62% |
| 2021 | 3.73 Million AUD | 28.31% |
| 2020 | 2.9 Million AUD | 59.12% |
| 2019 | 1.82 Million AUD | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q2 | 3.27 Million AUD | 100.0% |
| 2024 FY | 12.09 Million AUD | 123.06% |
| 2024 Q1 | 1.63 Million AUD | -49.94% |
| 2024 Q4 | 8.81 Million AUD | 0.0% |
| 2023 Q1 | 1.07 Million AUD | -56.79% |
| 2023 Q4 | 3.26 Million AUD | 100.0% |
| 2023 FY | 5.42 Million AUD | 15.6% |
| 2023 Q3 | 1.63 Million AUD | -24.04% |
| 2023 Q2 | 2.15 Million AUD | 100.0% |
| 2022 Q1 | 1.09 Million AUD | -46.09% |
| 2022 Q4 | 2.48 Million AUD | 100.0% |
| 2022 FY | 4.68 Million AUD | 25.62% |
| 2022 Q3 | 1.24 Million AUD | -43.38% |
| 2022 Q2 | 2.19 Million AUD | 100.0% |
| 2021 Q3 | 1.01 Million AUD | -39.76% |
| 2021 FY | 3.73 Million AUD | 28.31% |
| 2021 Q4 | 2.03 Million AUD | 100.0% |
| 2021 Q2 | 1.69 Million AUD | 100.0% |
| 2021 Q1 | 846.46 Thousand AUD | 0.0% |
| 2020 FY | 2.9 Million AUD | 59.12% |
| 2019 FY | 1.82 Million AUD | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Australian Clinical Labs Limited | 689.72 Million AUD | 98.247% |
| BCAL Diagnostics Limited | 3.09 Million AUD | -290.241% |
| Genetic Signatures Limited | 9.76 Million AUD | -23.797% |
| Genetic Technologies Limited | 7.66 Million AUD | -57.735% |
| Healius Limited | 1.74 Billion AUD | 99.308% |
| Imagion Biosystems Limited | 1.36 Million AUD | -784.114% |
| Integral Diagnostics Limited | 469.69 Million AUD | 97.426% |
| INOVIQ Ltd | 535.11 Thousand AUD | -2159.325% |
| Monash IVF Group Limited | 254.96 Million AUD | 95.258% |
| Rhythm Biosciences Limited | 1.69 Million AUD | -615.327% |
| Sonic Healthcare Limited | 8.93 Billion AUD | 99.865% |